Abstract
Germline mutations of the LKB1 gene are responsible for Peutz–Jeghers syndrome (PJS), an autosomal dominant inherited disorder bestowing an increased risk of cancer. We have recently demonstrated that LKB1 inactivating mutations are not confined to PJS, but also appear in lung adenocarcinomas of sporadic origin, including primary tumors and lung cancer cell lines. To accurately determine the frequency of inactivating LKB1 gene mutations in lung tumors we have sequenced the complete coding region of LKB1 in 21 additional lung cancer cell lines. Here we describe the mutational status of LKB1 gene in 30 lung cancer cell lines from different histopathological types, including 11 lung adenocarcinomas (LADs) and 11 small cell lung cancers (SCLCs). LKB1 gene alterations were present in six (54%) of the LAD cell lines tested but in none of the other histological types. Similar to our previous observations in primary tumors, all point mutations were of the nonsense or frameshift type, leading to an abnormal, truncated protein. Moreover, 2 cell lines (A427 and H2126) harbored large gene deletions that spanned several exons. Hence, we have identified additional lung cancer cell lines carrying inactivating mutations of the LKB1 tumor suppressor gene, further attesting to the significance of this gene in the development of LADs and providing new natural LKB1 knockouts for studies of the biological function of the LKB1 protein.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ and Sidransky D . (2001). Cancer, 92, 1525–1530.
Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, Salovaara R, Arola J, Butzow R, Husgafvel-Pursiainen K, Kokkola A, Jarvinen H and Aaltonen LA . (1999). Am. J. Pathol., 154, 677–681.
Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, Alessi DR and Clevers HC . (2003). EMBO J., 22, 3062–3072.
Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC and Alessi DR . (2003). EMBO J., 22, 5102–5114.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 27, 949–954.
Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, Krush AJ, Yardley JH and Luk GD . (1987). N. Engl. J. Med., 316, 1511–1514.
Hainaut P and Pfeifer GP . (2001). Carcinogenesis, 22, 367–374.
Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR and Hardie DG . (2003). J. Biol., 2, 28.
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A and Aaltonen LA . (1998). Nature, 18, 184–187.
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W and Zimmer M . (1998). Nat. Genet., 18, 38–44.
Jimenez AI, Fernandez P, Dominguez O, Dopazo A and Sanchez-Cespedes M . (2003). Cancer Res., 63, 1382–1388.
Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, Brien TP, Bozzuto CD, Ooi D, Cantley LC and Yuan J . (2001). Mol. Cell., 7, 1307–1319.
Marignani PA, Kanai F and Carpenter CL . (2001). J. Biol. Chem., 276, 32415–32418.
Miyaki M, Iijima T, Hosono K, Ishii R, Yasuno M, Mori T, Toi M, Hishima T, Shitara N, Tamura K, Utsunomiya J, Kobayashi N, Kuroki T and Iwama T . (2000). Cancer Res., 60, 6311–6313.
Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P . (2002). Oncogene, 21, 7435–7451.
Sanchez-Cespedes M . (2003). Lung Cancer, 40, 111–121.
Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J and Sidransky D . (2001). Cancer Res., 61, 1309–1313.
Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky D . (2002). Cancer Res., 62, 3659–3662.
Smith DP, Rayter SI, Niederlander C, Spicer J, Jones CM and Ashworth A . (2001). Hum. Mol. Genet., 25, 2869–2877.
Spicer J, Rayter S, Young N, Elliott R, Ashworth A and Smith D . (2003). Oncogene, 22, 4752–4756.
Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, Goggins M, Yeo CJ and Kern SE . (1999). Am. J. Pathol., 154, 1835–1840.
Tiainen M, Ylikorkala A and Makela TP . (1999). Proc. Natl. Acad. Sci. USA, 96, 9248–9251.
Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD and Gazdar AF . (1998). Genes Chrom. Cancer, 21, 308–319.
Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M and Carling D . (2003). Curr. Biol., 13, 2004–2008.
Acknowledgements
The research was supported by a grant from the Spanish Ministerio de Ciencia y Tecnología (SAF2002-01595) and by a grant from the Comunidad de Madrid (CAM 08.1/0032/2003 1). Julian Carretero is a postdoctoral fellow of the Excmo, Ayuntamiento de Madrid, Pedro P Medina is supported by a Comunidad Autonoma de Madrid fellowship and Montserrat Sanchez-Cespedes is supported by the Ramon y Cajal Program from the Ministerio de Ciencia y Tecnología, Spain.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carretero, J., Medina, P., Pio, R. et al. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 23, 4037–4040 (2004). https://doi.org/10.1038/sj.onc.1207502
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207502
Keywords
This article is cited by
-
Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity
Signal Transduction and Targeted Therapy (2024)
-
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
Journal of Hematology & Oncology (2019)
-
Controlling the master—upstream regulation of the tumor suppressor LKB1
Oncogene (2018)
-
Targeting LKB1 in cancer – exposing and exploiting vulnerabilities
British Journal of Cancer (2015)
-
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
British Journal of Cancer (2013)